Literature DB >> 2984772

Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide.

W C Koff, S D Showalter, B Hampar, I J Fidler.   

Abstract

Intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine, a lipophilic derivative of muramyl dipeptide that activates macrophages to a cytolytic state in situ, significantly protected mice against lethal challenge with herpes simplex virus type 2. These findings suggest that the systemic activation of macrophages by liposomes containing an immunomodulator can lead to prophylaxis of severe infections caused by herpesviruses.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2984772     DOI： 10.1126/science.2984772

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  16 in total

1.  Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis.

Authors:  M Khor; D B Lowrie; A R Coates; D A Mitchison
Journal:  Br J Exp Pathol       Date:  1986-08

2.  Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection.

Authors:  P M Melissen; W van Vianen; Y Rijsbergen; I A Bakker-Woudenberg
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

3.  Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model.

Authors:  N Weiner; N Williams; G Birch; C Ramachandran; C Shipman; G Flynn
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 4.  Immunomodulating peptides.

Authors:  G H Werner; F Floc'h; D Migliore-Samour; P Jollès
Journal:  Experientia       Date:  1986-05-15

Review 5.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27

Review 6.  Liposomes in treatment of infectious diseases.

Authors:  F Emmen; G Storm
Journal:  Pharm Weekbl Sci       Date:  1987-06-19

7.  Prevention of oncogenic viral infections in mice with CGP 11637, a synthetic muramyl dipeptide analog.

Authors:  H F Acevedo; R B Raikow; H O Acevedo; T F Delgado; M Pardo
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

8.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

Authors:  A Gabizon; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

9.  Induction of macrophage antitumor activity by acetylated low density lipoprotein containing lipophilic muramyl tripeptide.

Authors:  J M Shaw; W S Futch; L B Schook
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

10.  Roles of peripheral leukocytes and tissue macrophages in antibacterial resistance induced by free or liposome-encapsulated muramyl tripeptide phosphatidylethanolamide.

Authors:  P M Melissen; W van Vianen; I A Bakker-Woudenberg
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.